Novo Nordisk stock falls after FDA warning letter

Novo Nordisk's stock experienced a decline following a warning letter from the FDA concerning potential violations in manufacturing quality. The warning raises concerns about the company's compliance practices and could lead to delays in product approvals or further regulatory scrutiny. Investors reacted negatively to the news, signaling a loss of confidence in the company's operations. The market is likely to remain cautious as more details about the FDA's findings become available. Overall, this situation may affect Novo Nordisk's short-term performance and investor sentiment significantly.